177 related articles for article (PubMed ID: 16711251)
1. Proposed reference material for human free immunoglobulin light chain measurement.
Nakano T; Miyazaki S; Shinoda Y; Inoue I; Katayama S; Komoda T; Nagata A
J Immunoassay Immunochem; 2006; 27(2):129-37. PubMed ID: 16711251
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
3. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
4. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method.
Nakano T; Nagata A
J Immunol Methods; 2004 Oct; 293(1-2):183-9. PubMed ID: 15541287
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of measurement of free light chains].
Matsuda M
Rinsho Byori; 2010 Apr; 58(4):401-4. PubMed ID: 20496770
[TBL] [Abstract][Full Text] [Related]
6. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
Shaheen SP; Levinson SS
Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
[TBL] [Abstract][Full Text] [Related]
7. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
8. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease.
Kaplan B; Ramirez-Alvarado M; Sikkink L; Golderman S; Dispenzieri A; Livneh A; Gallo G
Br J Haematol; 2009 Mar; 144(5):705-15. PubMed ID: 19076171
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
11. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
[TBL] [Abstract][Full Text] [Related]
13. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion.
Alyanakian MA; Abbas A; Delarue R; Arnulf B; Aucouturier P
Am J Hematol; 2004 Apr; 75(4):246-8. PubMed ID: 15054820
[TBL] [Abstract][Full Text] [Related]
14. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.
Gottenberg JE; Aucouturier F; Goetz J; Sordet C; Jahn I; Busson M; Cayuela JM; Sibilia J; Mariette X
Ann Rheum Dis; 2007 Jan; 66(1):23-7. PubMed ID: 16569685
[TBL] [Abstract][Full Text] [Related]
15. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Nowrousian MR; Brandhorst D; Sammet C; Kellert M; Daniels R; Schuett P; Poser M; Mueller S; Ebeling P; Welt A; Bradwell AR; Buttkereit U; Opalka B; Flasshove M; Moritz T; Seeber S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8706-14. PubMed ID: 16361557
[TBL] [Abstract][Full Text] [Related]
16. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.
Tate JR; Mollee P; Dimeski G; Carter AC; Gill D
Clin Chim Acta; 2007 Feb; 376(1-2):30-6. PubMed ID: 16945362
[TBL] [Abstract][Full Text] [Related]
17. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
Kaplan B; Ramirez-Alvarado M; Dispenzieri A; Zeldenrust SR; Leung N; Livneh A; Gallo G
Clin Chem Lab Med; 2008; 46(3):335-41. PubMed ID: 18254719
[TBL] [Abstract][Full Text] [Related]
18. Complementarily of urine analysis and serum free light chain assay for assessing response treatment response: illustrated by three case examples.
Levinson SS
Clin Chim Acta; 2011 Nov; 412(23-24):2206-10. PubMed ID: 21864518
[TBL] [Abstract][Full Text] [Related]
19. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
20. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective.
Nakano T; Miyazaki S; Takahashi H; Matsumori A; Maruyama T; Komoda T; Nagata A
Clin Chem Lab Med; 2006; 44(5):522-32. PubMed ID: 16681419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
